Nina-Sophie Schmidt-Hegemann

LMU Klinikum

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Claus Belka

Ludwig-Maximilians-Universität München

102

Chukwuka Eze

LMU Klinikum

Ute Ganswindt

Innsbruck Medical University

Constantinos Zamboglou

University of Freiburg

Christian G. Stief

LMU Klinikum

Anca‐Ligia Grosu

German Cancer Research Center

Peter Bartenstein

Ludwig-Maximilians-Universität München

Minglun Li

LMU Klinikum

Paul Rogowski

LMU Klinikum

Matthias Gückenberger

University Hospital of Zurich

Cooperative Institutions

Ludwig-Maximilians-Universität München

161

LMU Klinikum

137

German Cancer Research Center

Deutschen Konsortium für Translationale Krebsforschung

München Klinik

Heidelberg University

Klinik und Poliklinik für Nuklearmedizin

University of Freiburg

University Medical Center Freiburg

Technical University of Munich

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Expression Patterns of TOP2A and SIRT1 Are Predictive of Survival in Patients with High-Risk Soft Tissue Sarcomas Treated with a Neoadjuvant Anthracycline-Based Chemotherapy

Cancers (2021)

Luc M. Berclaz A. Altendorf-Hofmann Hans Roland Dürr Alexander Klein Martin K. Angele

Molecular predictors of response to chemotherapy and survival have not been put into clinical practice in high-risk soft tissue sarcomas (HR-STS) by now. The expression of TOP2A and SIRT1 has implications for the mechanism of action of doxorubicin, which is the backbone of chemotherapy in HR-STS. Pre-treatment samples of 167 patients with HR-STS were collected. Protein expression levels of TOP2A and SIRT1 were evaluated with tissue microarrays and immunohistochemistry and correlated with clinicopathological parameters, including overall survival (OS). The expression of TOP2A and SIRT1 was seen in 47% and 60% of patients with HR-STS, respectively. TOP2A expression was associated with higher tumor grading and shorter 5-year OS. The expression of SIRT1 was correlated with a better 5- and 10-year OS. The combination of high SIRT1 and low TOP2A ("Top survivors") significantly predicted a better OS compared to other biomarker combinations. A multivariate analysis confirmed the expression of SIRT1 and the "Top survivor" biomarker combination as independent predictive factors of OS. This is the first study to associate SIRT1 overexpression with a statistically significant prolongation of OS in HR-STS. Both individual markers and their combination can be used as predictive indicators for HR-STS patients scheduled for neoadjuvant anthracycline-based chemotherapy.

Tissue microarray

Grading (engineering)

10.3390/cancers13194877

Cite

Citations (9)

Metastasis-free survival after salvage radiotherapy for post-operative prostate cancer patients in the PSMA PET/CT era – a multicenter analysis

European Urology Open Science (2021)

Constantinos Zamboglou Nina-Sophie Schmidt-Hegemann Louise Emmett Iosif Strouthos Konstantinos Ferentinos

Salvage therapy

10.1016/s2666-1683(21)03122-0

Cite

Citations (0)

3611: ESTRO-ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy

Radiotherapy and Oncology (2024)

Piet Dirix Alan Dal Pra Vincent Khoo C. Carrié C. Cozzarini

10.1016/s0167-8140(24)03469-8

Cite

Citations (0)

Verträglichkeit und Effektivität der Strahlentherapie der pelvinen Lymphbahnen bei Patienten mit Prostatakarzinom

Nina-Sophie Schmidt-Hegemann

122 Patienten mit Strahlentherapie der pelvinen Lymphabflusswege bei Prostatakarzinom sind hinsichtlich der Vertraglichkeit und Effektivitat untersucht worden. Bei niedriger Rate an Spattoxizitat lag die Rate fur Lymphknotenmetastasen fur alle Patienten zwischen 3,0% (Primar bestrahlte Patienten ohne Lymphknoten-/Fernmetastasen) und 100% (Primar bestrahlte Patienten mit Lymphknoten- und Fernmetastasen) nach 3 Jahren. Von einer Dosiseskalation in den pelvinen Lymphabflusswegen/befallenen Lymphknoten konnten insbesondere folgende Untergruppen profitieren: primar zu bestrahlende lymphknotenpositive Patienten und postoperativ zu bestrahlende in adjuvanter/additiver Situation, mit biochemischen oder Lokal-/Lymphknotenrezidiv.

Source

Cite

Citations (0)

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Radiotherapy and Oncology (2023)

Sophia Scharl Constantinos Zamboglou Iosif Strouthos Andrea Farolfi Francesca Serani

Biochemical recurrence

Univariate analysis

Clinical endpoint

Glutamate carboxypeptidase II

10.1016/j.radonc.2023.109678

Cite

Citations (12)

Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T

Biomedicines (2022)

Lena M. Unterrainer Leonie Beyer Mathias J. Zacherl Franz Josef Gildehaus Andrei Todica

Background: PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV) on PSMA PET impacts therapy outcomes and plays an increasing role in mCRPC patients. Hence, we aimed to assess TTV and its changes during 225Ac-PSMA-I&T RLT. Methods: mCRPC patients undergoing RLT with 225Ac-PSMA-I&T with available 18F-PSMA-1007 PET/CT prior to therapy initiation were included. TTV was assessed in all patients using established cut-off values. Image derived, clinical and biochemistry parameters (PSA, LDH, AP, pain score) were analyzed prior to and after two cycles of 225Ac-PSMA. Changes in TTV and further parameters were directly compared and then correlated with established response criteria, such as RECIST 1.1 or mPERCIST. Results: 13 mCRPC patients were included. The median overall survival (OS) was 10 months. Prior to 225Ac-PSMA RLT, there was no significant correlation between TTV with other clinical parameters (p > 0.05 each). Between short-term survivors (STS, <10 months OS) and long-term survivors (LTS, ≥10 months OS), TTV and PSA were comparable (p = 0.592 & p = 0.286, respectively), whereas AP was significantly lower in the LTS (p = 0.029). A total of 7/13 patients completed two cycles and underwent a follow-up 18F-PSMA-1007 PET/CT. Among these patients, there was a significant decrease in TTV (median 835 vs. 201 mL, p = 0.028) and PSA (median 687 ng/dL vs. 178 ng/dL, p = 0.018) after two cycles of 225Ac-PSMA RLT. Here, percentage changes of TTV after two cycles showed no direct correlation to all other clinical parameters (p > 0.05 each). In two patients, new PET-avid lesions were detected on 18F-PSMA-1007 PET/CT. However, TTV and PSA were decreasing or stable. Conclusion: PET-derived assessment of TTV is an easily applicable imaging biomarker independent of other established parameters prior to 225Ac-PSMA RLT in these preliminary follow-up data. Even after the failure of 177Lu-PSMA, patients with extensive TTV seem to profit from RLT. All but one patient who was eligible for ≥2 cycles of 225Ac-PSMA-RLT demonstrated drastic TTV decreases without direct correlation to other biomarkers, such as serum PSA changes. Changes in TTV might hence improve the response assessment compared to standard classifiers by reflecting the current tumor load independent of the occurrence of new lesions.

Radionuclide therapy

10.3390/biomedicines10050946

Cite

Citations (13)

Development of PSMA-PET-guided CT-based radiomic signature to predict biochemical recurrence after salvage radiotherapy

European Journal of Nuclear Medicine and Molecular Imaging (2023)

Simon K. B. Spohn Nina-Sophie Schmidt-Hegemann Juri Ruf Michael Mix Matthias Benndorf

To develop a CT-based radiomic signature to predict biochemical recurrence (BCR) in prostate cancer patients after sRT guided by positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET).

Biochemical recurrence

Glutamate carboxypeptidase II

breakpoint cluster region

Salvage therapy

10.1007/s00259-023-06195-3

Cite

Citations (13)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis

European Journal of Nuclear Medicine and Molecular Imaging (2022)

Simon K. B. Spohn Andrea Farolfi Sarah Schandeler Marco M. E. Vogel Juri Ruf

Abstract Purpose This study aims to evaluate the association of the maximum standardized uptake value (SUVmax) in positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET) prior to salvage radiotherapy (sRT) on biochemical recurrence free survival (BRFS) in a large multicenter cohort. Methods Patients who underwent 68 Ga-PSMA11-PET prior to sRT were enrolled in four high-volume centers in this retrospective multicenter study. Only patients with PET-positive local recurrence (LR) and/or nodal recurrence (NR) within the pelvis were included. Patients were treated with intensity-modulated-sRT to the prostatic fossa and elective lymphatics in case of nodal disease. Dose escalation was delivered to PET-positive LR and NR. Androgen deprivation therapy was administered at the discretion of the treating physician. LR and NR were manually delineated and SUVmax was extracted for LR and NR. Cox-regression was performed to analyze the impact of clinical parameters and the SUVmax-derived values on BRFS. Results Two hundred thirty-five patients with a median follow-up (FU) of 24 months were included in the final cohort. Two-year and 4-year BRFS for all patients were 68% and 56%. The presence of LR was associated with favorable BRFS ( p = 0.016). Presence of NR was associated with unfavorable BRFS ( p = 0.007). While there was a trend for SUVmax values ≥ median ( p = 0.071), SUVmax values ≥ 75% quartile in LR were significantly associated with unfavorable BRFS ( p = 0.022, HR: 2.1, 95%CI 1.1–4.6). SUVmax value in NR was not significantly associated with BRFS. SUVmax in LR stayed significant in multivariate analysis ( p = 0.030). Sensitivity analysis with patients for who had a FU of > 12 months ( n = 197) confirmed these results. Conclusion The non-invasive biomarker SUVmax can prognosticate outcome in patients undergoing sRT and recurrence confined to the prostatic fossa in PSMA-PET. Its addition might contribute to improve risk stratification of patients with recurrent PCa and to guide personalized treatment decisions in terms of treatment intensification or de-intensification. This article is part of the Topical Collection on Oncology—Genitourinary.

Salvage therapy

10.1007/s00259-022-05931-5

Cite

Citations (21)

The Co-IMPACT Consortium: Integrating Prostate-specific Membrane Antigen Positron Emission Tomography and Radiotherapy in Prostate Cancer Care

European Urology (2025)

Vedang Murthy Giulia Marvaso Barbara Alicja Jereczek‐Fossa S Thoma Marco M. E. Vogel

Glutamate carboxypeptidase II

10.1016/j.eururo.2025.01.003

Cite

Citations (0)

EP-1522 Radiotherapy with or without antihormonal therapy for PSMA-positive oligorecurrent prostate cancer

Radiotherapy and Oncology (2019)

Stephanie Kroeze Christoph Henkenberens Nina-Sophie Schmidt-Hegemann Marco M. E. Vogel Simon Kirste

benefit of metastasis-directed therapy.However, specific response criteria for PSMA-PET/CT are urgently needed.Also, an interval of more than 6 months may be required to fully estimate the local efficacy of SABR in control PSMA-PET/CT in some patients.

10.1016/s0167-8140(19)31942-5

Cite

Citations (0)